

Molecular Cytogenetics Market by Product (Kits, Reagents, Probes, Instrument, Software, Services), Technique (FISH, CISH, Comparative Genomic Hybridization (Array-based, Standard)), Application (Cancer, Genetics Disorders) - Global Forecast to 2028

Market Report | 2024-01-24 | 235 pages | MarketsandMarkets

AVAILABLE LICENSES:

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

Report description:

The molecular cytogenetics market is valued at an estimated USD 3.1 billion in 2023 and is projected to reach USD 4.9 billion by 2028, at a CAGR of 9.9% during the forecast period. Increasing in the incidence of chronic diseases like cancer and genetic diseases has led to the increase in prevalence of the diagnosis of the diseases at earlier stage and diagnosis of the core cause of disease. Urgent and timely treatment is required to manage these patients. The overall increase in the number of research and diagnostic procedures is leading to the increased adoption of molecular cytogenetics in order to ensure the accurate diagnosis of the diseases. This is driving the overall growth of the market.

"Kits & Reagents segment accounted for the highest growth rate in the molecular cytogenetics market, by product, during the forecast period."

The molecular cytogenetics market is bifurcated into kits & reagents, instruments, consumables and software & services on the basis of product. The kits & reagents segment in the molecular cytogenetics market is experiencing substantial growth, largely driven by the increasing incidence of diseases such as cancers and increasing focus on personalized medicines.

"Comparative genomic hybridization segment accounted for the highest growth rate in the molecular cytogenetics market, by technique, during the forecast period."

The molecular cytogenetics market is bifurcated into comparative genomic hybridization, fluorescence in-situ hybridization, chromogenic in-situ hybridization and other techniques on the basis of technique. The comparative genomic hybridization segment in the molecular cytogenetics market is experiencing substantial growth, largely driven by the increasing penetration of molecular cytogenetics in clinical pathology and research.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

"Cancer segment accounted for the highest growth rate in the molecular cytogenetics market, by applications, during the forecast period."

The global molecular cytogenetics market is bifurcated into genetic disorders, cancer, personalized medicine and other applications. The cancer segment is currently witnessing the highest growth rate within the molecular cytogenetics market. The rising geriatric population and rising incidence of cancer due to genetic changes are the major factors driving this segment's growth.

"Clinical & research laboratories segment accounted for the highest CAGR"

Based on end users, the molecular cytogenetics market is segmented into clinical & research laboratories, academic research institutes, pharmaceutical & biotechnology companies and other end users. In 2022, the clinical & research laboratories segment accounted for the highest growth rate. This can be attributed to the increased demand for advanced cytogenetics products for disease diagnosis.

"Asia Pacific: The fastest-growing region molecular cytogenetics market"

The global molecular cytogenetics market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is projected to register the highest CAGR during the forecast period. Anticipated growth in this region will primarily focus on China and Japan. Factors such as a growing elderly population, rising cancer prevalence, increased healthcare expenditures, higher per capita income, escalating demand for advanced technology, the expansion of private healthcare sectors across several APAC nations, and the existence of rapidly developing markets are steering the market's growth in this region.

The break-up of the profile of primary participants in the molecular cytogenetics market:

-□By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%

-□By Designation: C-level - 27%, D-level - 18%, and Others - 55%

-□By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America - 6%, and Middle East & Africa- 4%

The key players in this market are Thermo Fisher Scientific Inc. (US), Illumina Inc. (US), Danaher Corporation (US), F. Hoffmann-La Roche Ltd. (Switzerland), Revvity (US), Abbott Laboratories (US), Agilent Technologies, Inc. (US), Pacific Biosciences (US), Bio-Rad Laboratories, Inc. (US), Bio-Techne Corporation (US), GeneDx (US), Oncocyte Corporation (US), BioView (Israel), Oxford Gene Technology IP, Limited. (UK), Applied Spectral Imaging, Inc. (US), Cyto-Test Inc. (US), KromaTiD, Inc. (US), Genial Genetic Solutions, Ltd. (UK), Cytognomix, Inc. (Canada), MetaSystems (Germany), SciGene (US), Biomodal (UK), Biocare Medical (US), BioDot (US), OncoDNA (Belgium).

Research Coverage:

This research report categorizes the molecular cytogenetics market by product (kits & reagents, instruments, consumables and software & services), technique (comparative genomic hybridization, fluorescence in-situ hybridization, chromogenic in-situ hybridization and other techniques), application (genetic disorders, cancer, personalized medicine and other applications), end user (clinical & research laboratories, academic research institutes, pharmaceutical & biotechnology companies and other end users), and region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities and challenges, influencing the growth of the molecular cytogenetics market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions and services, key strategies, acquisitions, and agreements. New product launches and recent developments associated with the molecular cytogenetics market. Competitive analysis of upcoming startups in the molecular cytogenetics market ecosystem is covered in this report.

Reasons to buy this report:

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall molecular cytogenetics market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities and challenges.

The report provides insights on the following pointers:

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

-□Analysis of key drivers (increasing incidence of cancer and genetic disorders, growing focus on targeted cancer treatment, rapid growth in aging population and subsequent increase in prevalence of chronic diseases, increasing penetration of molecular cytogenetics in clinical pathological testing), restraints (high cost of advanced instruments, unfavorable reimbursement scenario), opportunities (untapped emerging markets in Asia) and challenges (transition from FISH to array-based techniques) influencing the growth of the molecular cytogenetics market.

-□Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the molecular cytogenetics market.

-□Market Development: Comprehensive information about lucrative markets - the report analyses the molecular cytogenetics market across varied regions.

-□Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the molecular cytogenetics market

-□Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players like F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), Agilent Technologies, Inc. (US), Abbott Laboratories (US), Thermo Fisher Scientific Inc. (US), among others in the molecular cytogenetics market strategies.

Table of Contents:

1	INTRODUCTION	27		
1.1	STUDY OBJECTIVES	27		
1.2	MARKET DEFINITION	27		
1.2.1	INCLUSIONS & EXCLUSIONS	28		
1.3	STUDY SCOPE	29		
1.3.1	MARKET SEGMENTATION	29		
1.3.2	GEOGRAPHIC SCOPE	30		
1.3.3	YEARS CONSIDERED	30		
1.4	CURRENCY	31		
1.5	LIMITATIONS	31		
1.6	STAKEHOLDERS	31		
1.7	SUMMARY OF CHANGES	31		
2	RESEARCH METHODOLOGY	33		
2.1	RESEARCH DATA	33		
2.2	RESEARCH APPROACH	33		
FIGURE 1			MOLECULAR CYTOGENETICS MARKET: RESEARCH DESIGN METHODOLOGY	33
2.2.1	SECONDARY DATA	34		
2.2.1.1	Key data from secondary sources	34		
2.2.2	PRIMARY DATA	35		
2.2.2.1	Primary sources	36		
2.2.2.2	Key data from primary sources	36		
2.2.2.3	Key industry insights	37		
2.2.2.4	Breakdown of primary interviews	37		
FIGURE 2			BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS	37
FIGURE 3			BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION	38
2.3	MARKET SIZE ESTIMATION	38		
2.3.1	BOTTOM-UP APPROACH	39		
2.3.1.1	Approach 1: Company revenue estimation approach	39		
FIGURE 4			BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH	39
2.3.1.2	Approach 2: Presentations of companies and primary interviews	39		
2.3.1.3	Growth forecast	40		

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

2.3.1.4	CAGR projections	40
FIGURE 5	CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS	40
2.3.2	TOP-DOWN APPROACH	41
FIGURE 6	MOLECULAR CYTOGENETICS MARKET: TOP-DOWN APPROACH	41
2.4	MARKET BREAKDOWN & DATA TRIANGULATION	42
FIGURE 7	DATA TRIANGULATION METHODOLOGY	42
2.5	MARKET SHARE ANALYSIS	43
2.6	STUDY ASSUMPTIONS	43
2.7	RISK ASSESSMENT	44
2.8	GROWTH RATE ASSUMPTIONS	44
2.9	RECESSION IMPACT	44
3	EXECUTIVE SUMMARY	47
FIGURE 8	MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION)	47
FIGURE 9	MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2023 VS. 2028 (USD MILLION)	48
FIGURE 10	MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)	48
FIGURE 11	MOLECULAR CYTOGENETICS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)	49
FIGURE 12	MOLECULAR CYTOGENETICS MARKET, BY REGION, 2023 VS. 2028 (USD MILLION)	50
4	PREMIUM INSIGHTS	51
4.1	MOLECULAR CYTOGENETICS MARKET OVERVIEW	51
FIGURE 13	RISING PREVALENCE OF CANCER AND GENETIC DISORDERS TO DRIVE MARKET	51
4.2	MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028	52
FIGURE 14	KITS & REAGENTS TO CONTINUE TO DOMINATE MARKET IN 2028	52
4.3	MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2023 VS. 2028	52
FIGURE 15	COMPARATIVE GENOMIC HYBRIDIZATION TO CONTINUE TO DOMINATE MOLECULAR CYTOGENETICS MARKET IN 2028	52
4.4	MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2023 VS. 2028	53
FIGURE 16	CANCER WILL CONTINUE TO DOMINATE MOLECULAR CYTOGENETICS MARKET IN 2028	53
4.5	MOLECULAR CYTOGENETICS MARKET, BY END USER, 2023 VS. 2028	53
FIGURE 17	CLINICAL & RESEARCH LABORATORIES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD	53
4.6	MOLECULAR CYTOGENETICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES	54
FIGURE 18	ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE IN MOLECULAR CYTOGENETICS MARKET DURING FORECAST PERIOD	54
5	MARKET OVERVIEW	55
5.1	INTRODUCTION	55
5.2	MARKET DYNAMICS	55
FIGURE 19	MOLECULAR CYTOGENETICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES	55
5.2.1	MARKET DRIVERS	56
5.2.1.1	Increasing incidence of cancer and genetic disorders	56
TABLE 1	PREVALENCE OF GENETIC DISORDERS (2021)	56
TABLE 2	ESTIMATED NUMBER OF NEW CANCER CASES GLOBALLY, BY TYPE OF CANCER, 2020 VS. 2025	57
TABLE 3	GLOBAL CANCER INCIDENCE, BY REGION, 2020 VS. 2025	57
5.2.1.2	Growing focus on targeted cancer treatment	58
5.2.1.3	Increasing aging population and subsequent rise in prevalence of chronic diseases	58
5.2.1.4	Increasing penetration of molecular cytogenetics in clinical pathological testing	59
5.2.2	MARKET RESTRAINTS	60
5.2.2.1	High cost of advanced instruments	60
5.2.2.2	Unfavorable reimbursement scenario	60
5.2.3	MARKET OPPORTUNITIES	61

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

5.2.3.1	Untapped emerging markets	61
5.2.4	MARKET CHALLENGES	61
5.2.4.1	Transition from FISH to array-based techniques	61
5.3	PRICING ANALYSIS	62
5.3.1	PRICING MODEL ANALYSIS	62
TABLE 4	INDICATIVE PRICING ANALYSIS FOR MOLECULAR CYTOGENETIC PRODUCTS	62
5.3.2	AVERAGE SELLING PRICE OF MOLECULAR CYTOGENETIC PRODUCTS, BY KEY PLAYER	62
TABLE 5	AVERAGE SELLING PRICE OF MOLECULAR CYTOGENETIC PRODUCTS	62
5.4	PATENT ANALYSIS	63
5.4.1	PATENT ANALYSIS OF MOLECULAR CYTOGENETIC PRODUCTS (JANUARY 2013-DECEMBER 2022)	63
5.4.2	MOLECULAR CYTOGENETICS MARKET: LIST OF MAJOR PATENTS	64
5.5	TRADE ANALYSIS	65
5.5.1	TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS	65
5.5.1.1	Import data for diagnostic and laboratory reagents, by country, 2018-2022 (USD million)	65
5.5.1.2	Export data for diagnostic and laboratory reagents, by country, 2018-2022 (USD million)	65
5.6	VALUE CHAIN ANALYSIS	66
FIGURE 20	VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES	66
5.7	SUPPLY CHAIN ANALYSIS	67
FIGURE 21	MOLECULAR CYTOGENETICS MARKET: SUPPLY CHAIN ANALYSIS	67
5.8	ECOSYSTEM ANALYSIS	68
FIGURE 22	MOLECULAR CYTOGENETICS MARKET: ECOSYSTEM ANALYSIS	68
5.8.1	ROLE IN ECOSYSTEM	68
TABLE 6	MOLECULAR CYTOGENETICS MARKET: ECOSYSTEM ROLE	68
5.9	PORTER'S FIVE FORCES ANALYSIS	69
TABLE 7	MOLECULAR CYTOGENETICS MARKET: PORTER'S FIVE FORCES ANALYSIS	69
5.9.1	THREAT OF NEW ENTRANTS	69
5.9.2	THREAT OF SUBSTITUTES	69
5.9.3	BARGAINING POWER OF BUYERS	69
5.9.4	BARGAINING POWER OF SUPPLIERS	69
5.9.5	INTENSITY OF COMPETITIVE RIVALRY	70
5.10	PESTLE ANALYSIS	70
5.11	REGULATORY ANALYSIS	71
TABLE 8	NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	71
TABLE 9	ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	71
TABLE 10	LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	72
TABLE 11	REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	72
5.11.1	NORTH AMERICA	72
5.11.1.1	US	72
5.11.1.2	Canada	72
5.11.2	EUROPE	73
TABLE 12	EUROPE: CLASSIFICATION OF DEVICES	73
5.11.3	ASIA PACIFIC	74
5.11.3.1	China	74
5.11.3.2	Japan	74
TABLE 13	JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS	74
5.11.3.3	India	74
5.11.4	LATIN AMERICA	75

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

5.11.4.1	Brazil	75
5.11.4.2	Mexico	75
5.11.5	MIDDLE EAST	75
5.11.6	AFRICA	76
5.12	KEY CONFERENCES & EVENTS IN 2022-2023	76
TABLE 14	MOLECULAR DIAGNOSTICS MARKET: DETAILED LIST OF CONFERENCES & EVENTS	76
5.13	TRENDS/DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS	77
FIGURE 23	REVENUE SHIFT AND REVENUE POCKETS FOR MOLECULAR CYTOGENETICS MARKET	77
5.14	KEY STAKEHOLDERS & BUYING CRITERIA	78
5.14.1	KEY STAKEHOLDERS IN BUYING PROCESS	78
FIGURE 24	INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR MOLECULAR CYTOGENETIC PRODUCTS	78
TABLE 15	INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR MOLECULAR CYTOGENETIC PRODUCTS (%)	78
5.14.2	BUYING CRITERIA	79
FIGURE 25	KEY BUYING CRITERIA FOR MOLECULAR CYTOGENETIC END USERS	79
TABLE 16	KEY BUYING CRITERIA	79
5.15	CASE STUDY ANALYSIS	79
5.15.1	CASE STUDY: CYTOGENETIC ANALYSIS OF WISKOTT-ALDRICH SYNDROME	79
6	MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE	81
6.1	INTRODUCTION	82
TABLE 17	MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)	82
6.2	KITS & REAGENTS	83
TABLE 18	MOLECULAR CYTOGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2021-2028 (USD MILLION)	83
TABLE 19	MOLECULAR CYTOGENETICS MARKET FOR KITS & REAGENTS, BY REGION, 2021-2028 (USD MILLION)	84
6.2.1	TESTING KITS	84
6.2.1.1	Growing advancements in test kits to support market growth	84
TABLE 20	MOLECULAR CYTOGENETICS MARKET FOR TESTING KITS, BY REGION, 2021-2028 (USD MILLION)	85
6.2.2	PROBES	85
6.2.2.1	Increased usage of probes for in situ hybridization to propel market	85
TABLE 21	MOLECULAR CYTOGENETICS MARKET FOR PROBES, BY REGION, 2021-2028 (USD MILLION)	86
6.2.3	FLUORESCENT AFFINITY REAGENTS	86
6.2.3.1	Development of novel cytogenetic reagents to drive growth	86
TABLE 22	MOLECULAR CYTOGENETICS MARKET FOR FLUORESCENT AFFINITY REAGENTS, BY REGION, 2021-2028 (USD MILLION)	87
6.2.4	OTHER KITS & REAGENTS	87
TABLE 23	MOLECULAR CYTOGENETICS MARKET FOR OTHER KITS & REAGENTS, BY REGION, 2021-2028 (USD MILLION)	87
6.3	INSTRUMENTS	88
6.3.1	INCREASING USAGE OF INSTRUMENTS IN DRUG DISCOVERY TO DRIVE MARKET	88
TABLE 24	MOLECULAR CYTOGENETICS MARKET FOR INSTRUMENTS, BY REGION, 2021-2028 (USD MILLION)	88
6.4	CONSUMABLES	89
6.4.1	INCREASING AWARENESS ABOUT EARLY-STAGE CANCER DIAGNOSIS TO DRIVE MARKET	89
TABLE 25	MOLECULAR CYTOGENETICS MARKET FOR CONSUMABLES, BY REGION, 2021-2028 (USD MILLION)	89
6.5	SOFTWARE & SERVICES	89
6.5.1	GROWING NEED FOR SOFTWARE SOLUTIONS FOR HIGH CONTENT SCREENING TO PROPEL MARKET	89
TABLE 26	MOLECULAR CYTOGENETICS MARKET FOR SOFTWARE & SERVICES, BY REGION, 2021-2028 (USD MILLION)	90
7	MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE	91
7.1	INTRODUCTION	92
TABLE 27	MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2028 (USD MILLION)	92
7.2	COMPARATIVE GENOMIC HYBRIDIZATION	92

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 28 □ MOLECULAR CYTOGENETICS MARKET FOR COMPARATIVE GENOMIC HYBRIDIZATION, BY TYPE, 2021-2028 (USD MILLION) □93

TABLE 29 □ MOLECULAR CYTOGENETICS MARKET FOR COMPARATIVE GENOMIC HYBRIDIZATION, BY REGION, 2021-2028 (USD MILLION) □93

7.2.1 □ ARRAY-BASED COMPARATIVE GENOMIC HYBRIDIZATION □94

7.2.1.1 □ Rising prevalence of human genetic disorders to support market growth □94

TABLE 30 □ MOLECULAR CYTOGENETICS MARKET FOR ARRAY-BASED COMPARATIVE GENOMIC HYBRIDIZATION, BY REGION, 2021-2028 (USD MILLION) □94

7.2.2 □ STANDARD COMPARATIVE GENOMIC HYBRIDIZATION □95

7.2.2.1 □ Increased focus on cancer research to drive growth □95

TABLE 31 □ MOLECULAR CYTOGENETICS MARKET FOR STANDARD COMPARATIVE GENOMIC HYBRIDIZATION, BY REGION, 2021-2028 (USD MILLION) □95

7.3 □ FLUORESCENCE IN SITU HYBRIDIZATION □95

7.3.1 □ ADVANCES IN FLUORESCENCE MICROSCOPY TO BOOST MARKET □95

TABLE 32 □ MOLECULAR CYTOGENETICS MARKET FOR FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2021-2028 (USD MILLION) □96

7.4 □ CHROMOGENIC IN SITU HYBRIDIZATION □96

7.4.1 □ COST-EFFECTIVENESS OVER FLUORESCENT IN SITU HYBRIDIZATION FISH TO SUPPORT ADOPTION □96

TABLE 33 □ MOLECULAR CYTOGENETICS MARKET FOR CHROMOGENIC IN SITU HYBRIDIZATION, BY REGION, 2021-2028 (USD MILLION) □97

7.5 □ OTHER TECHNIQUES □97

TABLE 34 □ MOLECULAR CYTOGENETICS MARKET FOR OTHER TECHNIQUES, BY REGION, 2021-2028 (USD MILLION) □98

8 □ MOLECULAR CYTOGENETICS MARKET, BY APPLICATION □99

8.1 □ INTRODUCTION □100

TABLE 35 □ MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION) □100

8.2 □ GENETIC DISORDERS □100

8.2.1 □ INCREASING EFFORTS TO STUDY GENETIC ACTIVITIES TO SUPPORT MARKET GROWTH □100

TABLE 36 □ MOLECULAR CYTOGENETICS MARKET FOR GENETIC DISORDERS, BY REGION, 2021-2028 (USD MILLION) □101

8.3 □ CANCER □101

8.3.1 □ STRATEGIC DEVELOPMENTS IN CANCER RESEARCH TO DRIVE MARKET GROWTH □101

TABLE 37 □ MOLECULAR CYTOGENETICS MARKET FOR CANCER, BY REGION, 2021-2028 (USD MILLION) □102

8.4 □ PERSONALIZED MEDICINE □102

8.4.1 □ INITIATIVES BY MARKET PLAYERS FOR PERSONALIZED MEDICINE TO SUPPORT MARKET GROWTH □102

TABLE 38 □ MOLECULAR CYTOGENETICS MARKET FOR PERSONALIZED MEDICINE, BY REGION, 2021-2028 (USD MILLION) □103

8.5 □ OTHER APPLICATIONS □103

TABLE 39 □ MOLECULAR CYTOGENETICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2021-2028 (USD MILLION) □104

9 □ MOLECULAR CYTOGENETICS MARKET, BY END USER □105

9.1 □ INTRODUCTION □106

TABLE 40 □ MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2028 (USD MILLION) □106

9.2 □ CLINICAL & RESEARCH LABORATORIES □106

9.2.1 □ GROWING RESEARCH INTENSITY TO DRIVE USAGE OF MOLECULAR CYTOGENETIC PRODUCTS □106

TABLE 41 □ MOLECULAR CYTOGENETICS MARKET FOR CLINICAL & RESEARCH INSTITUTES, BY REGION, 2021-2028 (USD MILLION) □107

9.3 □ ACADEMIC RESEARCH INSTITUTES □107

9.3.1 □ INCREASE IN RESEARCH FUNDING FOR LIFE SCIENCE PROJECTS TO DRIVE MARKET □107

TABLE 42 □ MOLECULAR CYTOGENETICS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY REGION, 2021-2028 (USD MILLION) □108

9.4 □ PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES □108

9.4.1 □ GROWING IMPORTANCE OF MOLECULAR CYTOGENETICS FOR DRUG DISCOVERY TO SUPPORT MARKET GROWTH □108

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 43 □ MOLECULAR CYTOGENETICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021-2028 (USD MILLION) □109

9.5 □ OTHER END USERS □109

TABLE 44 □ MOLECULAR CYTOGENETICS MARKET FOR OTHER END USERS, BY REGION, 2021-2028 (USD MILLION) □110

10 □ MOLECULAR CYTOGENETICS MARKET, BY REGION □111

10.1 □ INTRODUCTION □112

TABLE 45 □ MOLECULAR CYTOGENETICS MARKET, BY REGION, 2021-2028 (USD MILLION) □112

10.2 □ NORTH AMERICA □112

TABLE 46 □ LIST OF RELATED CONFERENCES HELD IN NORTH AMERICA □113

FIGURE 26 □ NORTH AMERICA: MOLECULAR CYTOGENETICS MARKET SNAPSHOT □113

TABLE 47 □ NORTH AMERICA: MOLECULAR CYTOGENETICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION) □114

TABLE 48 □ NORTH AMERICA: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION) □114

TABLE 49 □ NORTH AMERICA: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2028 (USD MILLION) □115

TABLE 50 □ NORTH AMERICA: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION) □115

TABLE 51 □ NORTH AMERICA: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2028 (USD MILLION) □116

10.2.1 □ NORTH AMERICA: RECESSION IMPACT □116

10.2.2 □ US □117

10.2.2.1 □ US to dominate North American molecular cytogenetics market □117

TABLE 52 □ US: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION) □118

TABLE 53 □ US: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2028 (USD MILLION) □118

TABLE 54 □ US: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION) □119

TABLE 55 □ US: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2028 (USD MILLION) □119

10.2.3 □ CANADA □119

10.2.3.1 □ Rising prevalence of cancer to drive market □119

TABLE 56 □ CANADA: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION) □120

TABLE 57 □ CANADA: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2028 (USD MILLION) □120

TABLE 58 □ CANADA: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION) □121

TABLE 59 □ CANADA: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2028 (USD MILLION) □121

10.3 □ EUROPE □122

FIGURE 27 □ EUROPE: CANCER INCIDENCE & MORTALITY, 2012-2035 □122

TABLE 60 □ EUROPE: MOLECULAR CYTOGENETICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION) □123

TABLE 61 □ EUROPE: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION) □123

TABLE 62 □ EUROPE: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2028 (USD MILLION) □124

TABLE 63 □ EUROPE: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION) □124

TABLE 64 □ EUROPE: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2028 (USD MILLION) □125

10.3.1 □ EUROPE: RECESSION IMPACT □125

10.3.2 □ GERMANY □125

10.3.2.1 □ Increasing healthcare expenditure with favorable government policies to propel market □125

TABLE 65 □ GERMANY: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION) □126

TABLE 66 □ GERMANY: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2028 (USD MILLION) □127

TABLE 67 □ GERMANY: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION) □127

TABLE 68 □ GERMANY: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2028 (USD MILLION) □128

10.3.3 □ UK □128

10.3.3.1 □ Availability of government funding and strategic collaborations to boost market □128

TABLE 69 □ UK: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION) □129

TABLE 70 □ UK: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2028 (USD MILLION) □129

TABLE 71 □ UK: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION) □130

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 72 UK: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2028 (USD MILLION) 130

10.3.4 FRANCE 130

10.3.4.1 Increasing government investments to boost growth of French molecular cytogenetics market 130

TABLE 73 FRANCE: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION) 131

TABLE 74 FRANCE: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2028 (USD MILLION) 132

TABLE 75 FRANCE: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 132

TABLE 76 FRANCE: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2028 (USD MILLION) 133

10.3.5 ITALY 133

10.3.5.1 Favorable funding scenario to drive adoption of molecular cytogenetics 133

TABLE 77 ITALY: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION) 134

TABLE 78 ITALY: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2028 (USD MILLION) 134

TABLE 79 ITALY: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 135

TABLE 80 ITALY: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2028 (USD MILLION) 135

10.3.6 SPAIN 135

10.3.6.1 Growing demand for genetic testing to create major growth opportunities for market players 135

TABLE 81 SPAIN: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION) 136

TABLE 82 SPAIN: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2028 (USD MILLION) 136

TABLE 83 SPAIN: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 137

TABLE 84 SPAIN: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2028 (USD MILLION) 137

10.3.7 REST OF EUROPE 138

TABLE 85 REST OF EUROPE: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION) 138

TABLE 86 REST OF EUROPE: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2028 (USD MILLION) 139

TABLE 87 REST OF EUROPE: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 139

TABLE 88 REST OF EUROPE: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2028 (USD MILLION) 140

10.4 ASIA PACIFIC 140

FIGURE 28 ASIA PACIFIC: MOLECULAR CYTOGENETICS MARKET SNAPSHOT 141

TABLE 89 ASIA PACIFIC: MOLECULAR CYTOGENETICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 142

TABLE 90 ASIA PACIFIC: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION) 142

TABLE 91 ASIA PACIFIC: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2028 (USD MILLION) 143

TABLE 92 ASIA PACIFIC: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 143

TABLE 93 ASIA PACIFIC: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2028 (USD MILLION) 144

10.4.1 ASIA PACIFIC: RECESSION IMPACT 144

10.4.2 CHINA 144

10.4.2.1 Increased cancer cases to propel market 144

TABLE 94 CHINA: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040 145

TABLE 95 CHINA: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION) 145

TABLE 96 CHINA: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2028 (USD MILLION) 146

TABLE 97 CHINA: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 146

TABLE 98 CHINA: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2028 (USD MILLION) 147

10.4.3 JAPAN 147

10.4.3.1 Universal health reimbursement policy to support market growth 147

TABLE 99 JAPAN: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION) 148

TABLE 100 JAPAN: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2028 (USD MILLION) 148

TABLE 101 JAPAN: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 149

TABLE 102 JAPAN: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2028 (USD MILLION) 149

10.4.4 INDIA 149

10.4.4.1 Increasing adoption of technology to support market growth 149

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 103	INDIA: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)	150
TABLE 104	INDIA: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2028 (USD MILLION)	151
TABLE 105	INDIA: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)	151
TABLE 106	INDIA: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2028 (USD MILLION)	152
10.4.5	REST OF ASIA PACIFIC	152
TABLE 107	REST OF ASIA PACIFIC: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)	153
TABLE 108	REST OF ASIA PACIFIC: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2028 (USD MILLION)	153
TABLE 109	REST OF ASIA PACIFIC: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)	154
TABLE 110	REST OF ASIA PACIFIC: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2028 (USD MILLION)	154
10.5	LATIN AMERICA	155
10.5.1	EXPANSIONS OF KEY PLAYERS IN LATIN AMERICAN REGION TO BOOST MARKET	155
TABLE 111	LATIN AMERICA: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)	155
TABLE 112	LATIN AMERICA: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2028 (USD MILLION)	156
TABLE 113	LATIN AMERICA: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)	156
TABLE 114	LATIN AMERICA: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2028 (USD MILLION)	157
10.5.2	LATIN AMERICA: RECESSION IMPACT	157
10.6	MIDDLE EAST & AFRICA	157
10.6.1	ADVANCEMENTS IN DIAGNOSTIC TECHNOLOGIES AND INCREASED HEALTHCARE INVESTMENT TO PROPEL MARKET	157
TABLE 115	MIDDLE EAST & AFRICA: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)	158
TABLE 116	MIDDLE EAST & AFRICA: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2028 (USD MILLION)	158
TABLE 117	MIDDLE EAST & AFRICA: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)	159
TABLE 118	MIDDLE EAST & AFRICA: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2028 (USD MILLION)	159
10.6.2	MIDDLE EAST & AFRICA: RECESSION IMPACT	159
11	COMPETITIVE LANDSCAPE	160
11.1	OVERVIEW	160
11.2	STRATEGIES OF KEY PLAYERS	160
11.2.1	OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN MOLECULAR CYTOGENETICS MARKET	160
TABLE 119	OVERVIEW OF STRATEGIES DEPLOYED BY KEY MOLECULAR CYTOGENETICS MANUFACTURING COMPANIES	160
11.3	REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS	162
FIGURE 29	REVENUE SHARE ANALYSIS OF TOP PLAYERS IN MOLECULAR CYTOGENETICS MARKET	162
11.4	MARKET SHARE ANALYSIS	163
FIGURE 30	MOLECULAR CYTOGENETICS MARKET SHARE, BY KEY PLAYER, 2022	163
TABLE 120	MOLECULAR CYTOGENETICS MARKET: DEGREE OF COMPETITION	164
11.5	COMPANY EVALUATION MATRIX	165
11.5.1	LIST OF EVALUATED VENDORS	165
11.5.2	STARS	165
11.5.3	EMERGING LEADERS	165
11.5.4	PERVASIVE PLAYERS	165
11.5.5	PARTICIPANTS	165
FIGURE 31	MOLECULAR CYTOGENETICS MARKET: COMPANY EVALUATION MATRIX, 2022	166
11.5.6	COMPANY FOOTPRINT ANALYSIS	167
TABLE 121	COMPANY TYPE FOOTPRINT	167
TABLE 122	COMPANY REGIONAL FOOTPRINT	167
11.6	STARTUP/SME EVALUATION MATRIX	168
11.6.1	PROGRESSIVE COMPANIES	168
11.6.2	RESPONSIVE COMPANIES	168
11.6.3	DYNAMIC COMPANIES	168

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

11.6.4	STARTING BLOCKS	168
FIGURE 32	MOLECULAR CYTOGENETICS MARKET: STARTUP/SME EVALUATION MATRIX, 2022	169
11.6.5	COMPETITIVE BENCHMARKING	170
FIGURE 33	PRODUCT AND REGIONAL FOOTPRINT ANALYSIS OF TOP PLAYERS IN MOLECULAR CYTOGENETICS MARKET	170
TABLE 123	MOLECULAR CYTOGENETICS MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS	170
11.7	COMPETITIVE SCENARIO & TRENDS	171
11.7.1	PRODUCT LAUNCHES	171
TABLE 124	KEY PRODUCT LAUNCHES & APPROVALS (JANUARY 2020-NOVEMBER 2023)	171
11.7.2	DEALS	171
TABLE 125	KEY DEALS (JANUARY 2020-NOVEMBER 2023)	171
11.7.3	OTHER DEVELOPMENTS	173
TABLE 126	OTHER DEVELOPMENTS (JANUARY 2020-NOVEMBER 2023)	173
12	COMPANY PROFILES	174
(Business Overview, Products Offered, Recent Developments, MnM View Right to win, Strategic choices made, Weaknesses and competitive threats) *		
12.1	KEY PLAYERS	174
12.1.1	F. HOFFMANN-LA ROCHE LTD.	174
TABLE 127	F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW	174
FIGURE 34	F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022)	175
12.1.2	DANAHER CORPORATION	179
TABLE 128	DANAHER CORPORATION: COMPANY OVERVIEW	179
FIGURE 35	DANAHER CORPORATION: COMPANY SNAPSHOT (2022)	180
12.1.3	AGILENT TECHNOLOGIES, INC.	183
TABLE 129	AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW	183
FIGURE 36	AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2022)	184
12.1.4	ABBOTT LABORATORIES	188
TABLE 130	ABBOTT LABORATORIES: COMPANY OVERVIEW	188
FIGURE 37	ABBOTT LABORATORIES: COMPANY SNAPSHOT (2022)	189
12.1.5	THERMO FISHER SCIENTIFIC, INC.	191
TABLE 131	THERMO FISHER SCIENTIFIC, INC.: COMPANY OVERVIEW	191
FIGURE 38	THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2022)	192
12.1.6	ILLUMINA INC.	195
TABLE 132	ILLUMINA INC.: COMPANY OVERVIEW	195
FIGURE 39	ILLUMINA INC.: COMPANY SNAPSHOT (2022)	196
12.1.7	REVVITY	199
TABLE 133	REVVITY: COMPANY OVERVIEW	199
FIGURE 40	REVVITY: COMPANY SNAPSHOT (2022)	200
12.1.8	PACIFIC BIOSCIENCES	202
TABLE 134	PACIFIC BIOSCIENCES: COMPANY OVERVIEW	202
FIGURE 41	PACIFIC BIOSCIENCES: COMPANY SNAPSHOT (2022)	203
12.1.9	BIO-RAD LABORATORIES, INC.	205
TABLE 135	BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW	205
FIGURE 42	BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2022)	206
12.1.10	BIO-TECHNE CORPORATION	209
TABLE 136	BIO-TECHNE CORPORATION: COMPANY OVERVIEW	209
FIGURE 43	BIO-TECHNE CORPORATION: COMPANY SNAPSHOT (2022)	210
12.1.11	GENEDX	213

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 137 GENEDX: COMPANY OVERVIEW 213
FIGURE 44 GENEDX: COMPANY SNAPSHOT (2022) 214
12.1.12 ONCOCYTE CORPORATION 216
TABLE 138 ONCOCYTE CORPORATION: COMPANY OVERVIEW 216
FIGURE 45 ONCOCYTE CORPORATION: COMPANY SNAPSHOT (2022) 216
12.1.13 BIOVIEW 218
TABLE 139 BIOVIEW: COMPANY OVERVIEW 218
12.2 OTHER PLAYERS 220
12.2.1 OXFORD GENE TECHNOLOGY IP LIMITED (PART OF SYSMEX) 220
12.2.2 APPLIED SPECTRAL IMAGING, INC. 222
12.2.3 CYTOTEST INC. 223
12.2.4 KROMATID, INC. 224
12.2.5 GENIAL GENETIC SOLUTIONS LTD. 225
12.2.6 CYTOGNOMIX, INC. 226
12.2.7 METASYSTEMS 227
12.2.8 SCIGENE 228
12.2.9 BIOMODAL 229
12.2.10 BIOCARE MEDICAL 230
12.2.11 BIODOT 231
12.2.12 ONCODNA 232

*Details on Business Overview, Products Offered, Recent Developments, MnM View, Right to win, Strategic choices made, Weaknesses and competitive threats might not be captured in case of unlisted companies.

13 APPENDIX 233
13.1 DISCUSSION GUIDE 233
13.2 KNOWLEDGESTORE: MARKETSDMARKETS' SUBSCRIPTION PORTAL 237
13.3 CUSTOMIZATION OPTIONS 239
13.4 RELATED REPORTS 239
13.5 AUTHOR DETAILS 240

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Molecular Cytogenetics Market by Product (Kits, Reagents, Probes, Instrument, Software, Services), Technique (FISH, CISH, Comparative Genomic Hybridization (Array-based, Standard)), Application (Cancer, Genetics Disorders) - Global Forecast to 2028

Market Report | 2024-01-24 | 235 pages | MarketsandMarkets

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Zip Code*

Country*

Date

2026-03-04

Signature

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com